Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population based study

Omar Mahmoud, Robert Beck, Evelyne Kalyoussef, Richard Chan Park, Soly Baredes, Sung Kim, Michael A Samuels

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose Head and neck soft tissue sarcoma (HNSTS) is a distinct entity within the soft tissue sarcoma group and the evidence supporting treatment options for this disease is poorly defined. Using the National Cancer Database, this study aims to reveal adjuvant therapy utilization patterns and their outcomes. Materials HNSTS patients constituted 6.5% of all sarcoma patients and the analysis was limited to non-metastatic patients who underwent resection between 2004 and 2012. Chi-square test assessed the distribution of demographic, tumor and treatment variables in the treatment subgroups. Kaplan-Meier method estimated overall survival and proportional hazards model estimated survival hazard ratios for prognostic factors including age, comorbidity, gender, race, size, grade, margin status, histology, chemotherapy administration and radiotherapy technique/dose. Results The cohort included 2493 patients with a median age of 62 years. Adjuvant therapies were more frequently delivered in high-grade, large tumors and with positive surgical margins. Limiting the analysis to 788 high-grade HNSTS patients, adjunctive radiotherapy improved 5-year survival from 44% (95% confidence interval (CI): 38–50) to 49% (CI: 43–55); reducing mortality hazards ratio by 24% (p < 0.001). On multivariate analysis, older age, positive surgical margins and large tumor size were significant predictors of poor survival. These findings were consistent after propensity score analysis. Conclusion Our analysis suggests that adjuvant radiotherapy is associated with improved survival in high-grade HNSTS. Higher dose and precise technique did not accentuate this benefit; however, further studies are needed to refine the treatment strategies, including the role of chemotherapy in the management of this rare disease.

Original languageEnglish (US)
Pages (from-to)28-37
Number of pages10
JournalOral Oncology
Volume66
DOIs
StatePublished - Mar 1 2017

Fingerprint

Sarcoma
Neck
Head
Survival
Population
Neoplasms
Radiotherapy
Therapeutics
Confidence Intervals
Drug Therapy
Propensity Score
Adjuvant Radiotherapy
Chi-Square Distribution
Rare Diseases
Proportional Hazards Models
Comorbidity
Histology
Multivariate Analysis
Demography
Databases

Keywords

  • Adjuvant chemotherapy
  • Adjuvant radiotherapy
  • Head and neck soft tissue sarcoma
  • Survival outcomes

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population based study. / Mahmoud, Omar; Beck, Robert; Kalyoussef, Evelyne; Chan Park, Richard; Baredes, Soly; Kim, Sung; Samuels, Michael A.

In: Oral Oncology, Vol. 66, 01.03.2017, p. 28-37.

Research output: Contribution to journalArticle

Mahmoud, Omar ; Beck, Robert ; Kalyoussef, Evelyne ; Chan Park, Richard ; Baredes, Soly ; Kim, Sung ; Samuels, Michael A. / Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population based study. In: Oral Oncology. 2017 ; Vol. 66. pp. 28-37.
@article{6bbfc57425fe468e9a9a3194a261087c,
title = "Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population based study",
abstract = "Purpose Head and neck soft tissue sarcoma (HNSTS) is a distinct entity within the soft tissue sarcoma group and the evidence supporting treatment options for this disease is poorly defined. Using the National Cancer Database, this study aims to reveal adjuvant therapy utilization patterns and their outcomes. Materials HNSTS patients constituted 6.5{\%} of all sarcoma patients and the analysis was limited to non-metastatic patients who underwent resection between 2004 and 2012. Chi-square test assessed the distribution of demographic, tumor and treatment variables in the treatment subgroups. Kaplan-Meier method estimated overall survival and proportional hazards model estimated survival hazard ratios for prognostic factors including age, comorbidity, gender, race, size, grade, margin status, histology, chemotherapy administration and radiotherapy technique/dose. Results The cohort included 2493 patients with a median age of 62 years. Adjuvant therapies were more frequently delivered in high-grade, large tumors and with positive surgical margins. Limiting the analysis to 788 high-grade HNSTS patients, adjunctive radiotherapy improved 5-year survival from 44{\%} (95{\%} confidence interval (CI): 38–50) to 49{\%} (CI: 43–55); reducing mortality hazards ratio by 24{\%} (p < 0.001). On multivariate analysis, older age, positive surgical margins and large tumor size were significant predictors of poor survival. These findings were consistent after propensity score analysis. Conclusion Our analysis suggests that adjuvant radiotherapy is associated with improved survival in high-grade HNSTS. Higher dose and precise technique did not accentuate this benefit; however, further studies are needed to refine the treatment strategies, including the role of chemotherapy in the management of this rare disease.",
keywords = "Adjuvant chemotherapy, Adjuvant radiotherapy, Head and neck soft tissue sarcoma, Survival outcomes",
author = "Omar Mahmoud and Robert Beck and Evelyne Kalyoussef and {Chan Park}, Richard and Soly Baredes and Sung Kim and Samuels, {Michael A}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.oraloncology.2016.12.030",
language = "English (US)",
volume = "66",
pages = "28--37",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population based study

AU - Mahmoud, Omar

AU - Beck, Robert

AU - Kalyoussef, Evelyne

AU - Chan Park, Richard

AU - Baredes, Soly

AU - Kim, Sung

AU - Samuels, Michael A

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose Head and neck soft tissue sarcoma (HNSTS) is a distinct entity within the soft tissue sarcoma group and the evidence supporting treatment options for this disease is poorly defined. Using the National Cancer Database, this study aims to reveal adjuvant therapy utilization patterns and their outcomes. Materials HNSTS patients constituted 6.5% of all sarcoma patients and the analysis was limited to non-metastatic patients who underwent resection between 2004 and 2012. Chi-square test assessed the distribution of demographic, tumor and treatment variables in the treatment subgroups. Kaplan-Meier method estimated overall survival and proportional hazards model estimated survival hazard ratios for prognostic factors including age, comorbidity, gender, race, size, grade, margin status, histology, chemotherapy administration and radiotherapy technique/dose. Results The cohort included 2493 patients with a median age of 62 years. Adjuvant therapies were more frequently delivered in high-grade, large tumors and with positive surgical margins. Limiting the analysis to 788 high-grade HNSTS patients, adjunctive radiotherapy improved 5-year survival from 44% (95% confidence interval (CI): 38–50) to 49% (CI: 43–55); reducing mortality hazards ratio by 24% (p < 0.001). On multivariate analysis, older age, positive surgical margins and large tumor size were significant predictors of poor survival. These findings were consistent after propensity score analysis. Conclusion Our analysis suggests that adjuvant radiotherapy is associated with improved survival in high-grade HNSTS. Higher dose and precise technique did not accentuate this benefit; however, further studies are needed to refine the treatment strategies, including the role of chemotherapy in the management of this rare disease.

AB - Purpose Head and neck soft tissue sarcoma (HNSTS) is a distinct entity within the soft tissue sarcoma group and the evidence supporting treatment options for this disease is poorly defined. Using the National Cancer Database, this study aims to reveal adjuvant therapy utilization patterns and their outcomes. Materials HNSTS patients constituted 6.5% of all sarcoma patients and the analysis was limited to non-metastatic patients who underwent resection between 2004 and 2012. Chi-square test assessed the distribution of demographic, tumor and treatment variables in the treatment subgroups. Kaplan-Meier method estimated overall survival and proportional hazards model estimated survival hazard ratios for prognostic factors including age, comorbidity, gender, race, size, grade, margin status, histology, chemotherapy administration and radiotherapy technique/dose. Results The cohort included 2493 patients with a median age of 62 years. Adjuvant therapies were more frequently delivered in high-grade, large tumors and with positive surgical margins. Limiting the analysis to 788 high-grade HNSTS patients, adjunctive radiotherapy improved 5-year survival from 44% (95% confidence interval (CI): 38–50) to 49% (CI: 43–55); reducing mortality hazards ratio by 24% (p < 0.001). On multivariate analysis, older age, positive surgical margins and large tumor size were significant predictors of poor survival. These findings were consistent after propensity score analysis. Conclusion Our analysis suggests that adjuvant radiotherapy is associated with improved survival in high-grade HNSTS. Higher dose and precise technique did not accentuate this benefit; however, further studies are needed to refine the treatment strategies, including the role of chemotherapy in the management of this rare disease.

KW - Adjuvant chemotherapy

KW - Adjuvant radiotherapy

KW - Head and neck soft tissue sarcoma

KW - Survival outcomes

UR - http://www.scopus.com/inward/record.url?scp=85008385071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008385071&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2016.12.030

DO - 10.1016/j.oraloncology.2016.12.030

M3 - Article

VL - 66

SP - 28

EP - 37

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -